Chondrite from Chelmugi.

Autor: Ternovoy, A. N., Belashev, B. Z., Shelekhova, T. S., Demidov, I. N.

Publikováno v: Inorganic Materials: Applied Research; Aug2024, Vol. 15 Issue 4, p1110-1118, 9p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of weekly carfilzomib (70 mg/m(2)), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

Autor: Leleu, X, Beksac, M, Chou, T, Dimopoulos, M, Yoon, SS, Prince, HM, Pour, L, Shelekhova, T, Chari, A, Khurana, M, Zhang, JQ, Obreja, M, Qi, M, Oriol, A, Siegel, D

Publikováno v: LEUKEMIA & LYMPHOMA
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m(2) carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT031

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::252e1c9085858eea5781da29b7947c90
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4000

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies

Autor: Leleu, X., Beksac, M., Chou, T., Dimopoulos, M., Yoon, S.S., Prince, H.M., Pour, L., Shelekhova, T., Chari, A., Khurana, M., Zhang, J., Obreja, M., Qi, M., Oriol, Albert, Siegel, D., Universitat Autònoma de Barcelona

Publikováno v: Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona

The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m2 carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::779b523ac619c8875a4d6f63391fce45
http://hdl.handle.net/2072/445092

Trip to Girvas

Autor: Shelekhova, T S, Svetov, S A, Medvedev, P V

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=httpsopenrep::4681323577520a93ee00ef020e19692e
https://openrepository.ru/article?id=656998